Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 6
2021 5
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B; SOLOIST-WHF Trial Investigators. Bhatt DL, et al. N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200892 Clinical Trial.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. Bhatt DL, et al. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200891 Clinical Trial.
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K; AMPLITUDE-O Trial Investigators. Gerstein HC, et al. N Engl J Med. 2021 Sep 2;385(10):896-907. doi: 10.1056/NEJMoa2108269. Epub 2021 Jun 28. N Engl J Med. 2021. PMID: 34215025 Clinical Trial.
Comments on the 2019 ESC guidelines on acute pulmonary embolism.
Working Group of the SEC for the 2019 ESC guidelines on acute pulmonary embolism, Expert Reviewers for the 2019 ESC guidelines on acute pulmonary embolism, and the SEC Guidelines Committee; Working Group of the SEC for the 2019 ESC guidelines on acute pulmonary embolism; SEC Guidelines Committee. Working Group of the SEC for the 2019 ESC guidelines on acute pulmonary embolism, Expert Reviewers for the 2019 ESC guidelines on acute pulmonary embolism, and the SEC Guidelines Committee, et al. Rev Esp Cardiol (Engl Ed). 2020 Jun;73(6):452-456. doi: 10.1016/j.rec.2019.12.022. Epub 2020 Apr 27. Rev Esp Cardiol (Engl Ed). 2020. PMID: 32349911 English, Spanish. No abstract available.
Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.
Amat-Santos IJ, Sánchez-Luna JP, Abu-Assi E, Melendo-Viu M, Cruz-Gonzalez I, Nombela-Franco L, Muñoz-Garcí AJ, Blas SG, de la Torre Hernandez JM, Romaguera R, Sánchez-Recalde Á, Diez-Gil JL, Lopez-Otero D, Gheorge L, Ibáñez B, Iñiguez-Romo A, Raposeiras-Roubín S; Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) Investigators. Amat-Santos IJ, et al. Eur J Heart Fail. 2022 Mar;24(3):581-588. doi: 10.1002/ejhf.2370. Epub 2021 Nov 9. Eur J Heart Fail. 2022. PMID: 34693613 Free article. Clinical Trial.
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, Leonsson-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalán R, Cornel JH, Widimský P, Leiter LA; THEMIS Steering Committee and Investigators. Steg PG, et al. N Engl J Med. 2019 Oct 3;381(14):1309-1320. doi: 10.1056/NEJMoa1908077. Epub 2019 Sep 1. N Engl J Med. 2019. PMID: 31475798 Free article. Clinical Trial.
Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation.
Escobar-Cervantes C, Díez-Villanueva P, Bonanad Lozano C, Reino AP, Almendro-Delia M, Facila L, Valle A, Suárez C. Escobar-Cervantes C, et al. Among authors: bonanad lozano c. Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(11):791-802. doi: 10.1080/14779072.2023.2276893. Epub 2023 Dec 10. Expert Rev Cardiovasc Ther. 2023. PMID: 37933665 Review.
Trade-off between the effects of embolic versus bleeding events on mortality in elderly patients with atrial fibrillation.
Raposeiras-Roubín S, Abu-Assi E, Cespón Fernández M, Blanco Prieto S, Barreiro Pardal C, Domínguez-Erquicia P, Melendo Viu M, Bonanad Lozano C, Rosselló X, Ibáñez B, Íñiguez Romo A. Raposeiras-Roubín S, et al. Among authors: bonanad lozano c. Rev Esp Cardiol (Engl Ed). 2022 Apr;75(4):334-342. doi: 10.1016/j.rec.2021.02.003. Epub 2021 Apr 8. Rev Esp Cardiol (Engl Ed). 2022. PMID: 33839062 English, Spanish.
Oxygen therapy and palliative care in patients with heart failure. Response.
García-Pinilla JM, Díez-Villanueva P, Crespo Leiro MG, Bonanad-Lozano C. García-Pinilla JM, et al. Among authors: bonanad lozano c. Rev Esp Cardiol (Engl Ed). 2020 Jul;73(7):599. doi: 10.1016/j.rec.2020.01.024. Epub 2020 May 4. Rev Esp Cardiol (Engl Ed). 2020. PMID: 32376230 English, Spanish. No abstract available.
[Impact of frailty and other geriatric syndromes on the clinical management and prognosis of elderly ambulatory patients with heart failure. A prospective and multicentre study].
Díez-Villanueva P, Salamanca J, Ariza-Solé A, Formiga F, Martín-Sánchez FJ, Bonanad Lozano C, Vidán MT, Martínez-Sellés M, Terres B, Jiménez Méndez C, Bueno H, Alfonso F. Díez-Villanueva P, et al. Among authors: bonanad lozano c. Rev Esp Geriatr Gerontol. 2020 Jan-Feb;55(1):29-33. doi: 10.1016/j.regg.2019.08.005. Epub 2019 Sep 9. Rev Esp Geriatr Gerontol. 2020. PMID: 31515087 Spanish.
11 results